🔗 Share this article The United States and United Kingdom Announce No-Tariff Pact on Drugs. Stock image of drug exports. Britain and America have secured a significant commercial pact that will guarantee zero tariffs on British pharmaceutical products entering the US market. The Terms of the Deal As part of the deal, the UK has committed to increase spending on pharmaceuticals through the National Health Service (NHS). This pledge secures that duties on these key exports will remain at zero for a duration of the next three years. This agreement follows earlier statements to dramatically increase import taxes on branded drug imports, with increases mentioned as high as double the cost. "This agreement with the Britain reinforces the worldwide climate for cutting-edge drugs and brings much-needed balance to U.S.–U.K. pharmaceutical trade," a statement noted. Trade Significance Medicines are one of the the United Kingdom's most significant export categories to the United States, which is clearly the biggest buyer for leading British pharmaceutical firms. Trade data indicate that in the one-year period to the end of September, the UK sold drugs worth billions to the US. This value made up 17.4% of all goods exports in that span. "This guarantee safeguards employment, stimulates funding and paves the way for the UK to establish itself as a worldwide center for medical research," a government official commented. Specific British Pledges The deal entails several key commitments from the UK: Price Threshold Increase: The UK will lift the affordability limit at which it deems new medicines to be unaffordable by a quarter. Higher Drug Budget: There is a target to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the following ten-year period. Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. In the past, refunds were more than 20%. Broader Context The deal comes amid a ongoing tension between the drug companies and the British authorities over spending levels and NHS adoption. These tensions were exacerbated by claims that American patients were paying significantly more for the equivalent treatments than people in the Britain and the EU. Over the last 18 months, several major drug company projects in the UK have been halted or scrapped, while major investments have been directed toward US facilities. A senior figure publicly accepted that the NHS had to spend more on treatments, noting that its spending on drugs had decreased as a proportion of its overall budget over the last ten years.
Stock image of drug exports. Britain and America have secured a significant commercial pact that will guarantee zero tariffs on British pharmaceutical products entering the US market. The Terms of the Deal As part of the deal, the UK has committed to increase spending on pharmaceuticals through the National Health Service (NHS). This pledge secures that duties on these key exports will remain at zero for a duration of the next three years. This agreement follows earlier statements to dramatically increase import taxes on branded drug imports, with increases mentioned as high as double the cost. "This agreement with the Britain reinforces the worldwide climate for cutting-edge drugs and brings much-needed balance to U.S.–U.K. pharmaceutical trade," a statement noted. Trade Significance Medicines are one of the the United Kingdom's most significant export categories to the United States, which is clearly the biggest buyer for leading British pharmaceutical firms. Trade data indicate that in the one-year period to the end of September, the UK sold drugs worth billions to the US. This value made up 17.4% of all goods exports in that span. "This guarantee safeguards employment, stimulates funding and paves the way for the UK to establish itself as a worldwide center for medical research," a government official commented. Specific British Pledges The deal entails several key commitments from the UK: Price Threshold Increase: The UK will lift the affordability limit at which it deems new medicines to be unaffordable by a quarter. Higher Drug Budget: There is a target to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the following ten-year period. Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. In the past, refunds were more than 20%. Broader Context The deal comes amid a ongoing tension between the drug companies and the British authorities over spending levels and NHS adoption. These tensions were exacerbated by claims that American patients were paying significantly more for the equivalent treatments than people in the Britain and the EU. Over the last 18 months, several major drug company projects in the UK have been halted or scrapped, while major investments have been directed toward US facilities. A senior figure publicly accepted that the NHS had to spend more on treatments, noting that its spending on drugs had decreased as a proportion of its overall budget over the last ten years.